Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study.

Saved in:
Bibliographic Details
Title: Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study.
Authors: Shields AM; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.; Department of Clinical Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom., Faustini SE; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Hill HJ; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Al-Taei S; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Tanner C; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Ashford F; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Workman S; Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom., Moreira F; Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom., Verma N; Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom., Wagg H; Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom., Heritage G; Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom., Campton N; Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom., Stamataki Z; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Drayson MT; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Klenerman P; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Thaventhiran JED; Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, United Kingdom., Elkhalifa S; Department of Immunology, Salford Royal NHS Foundation Trust, Salford, United Kingdom., Goddard S; Department of Clinical Immunology, University Hospitals North Midlands, Stoke-on-Trent, United Kingdom., Johnston S; Department of Clinical Immunology, North Bristol NHS Trust, Bristol, United Kingdom., Huissoon A; Department of Clinical Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom., Bethune C; Department of Allergy and Clinical Immunology, University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom., Elcombe S; Department of Allergy and Clinical Immunology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom., Lowe DM; Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom.; Institute of Immunity and Transplantation, University College London, London, United Kingdom., Patel SY; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.; National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) Oxford Biomedical Centre, University of Oxford, Oxford, United Kingdom., Savic S; Department of Allergy and Clinical Immunology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Richter AG; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.; Department of Clinical Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom., Burns SO; Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom.; Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Corporate Authors: COV-AD consortium
Source: Frontiers in immunology [Front Immunol] 2022 Jun 02; Vol. 13, pp. 912571. Date of Electronic Publication: 2022 Jun 02 (Print Publication: 2022).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2022.912571